RxDoctor Payments DataLook up a doctor →

Frank D'alessandro, MD

Internal Medicine · Lincoln, RINPI 1225018955

Payments from drug & device makers

$541,201in general payments, 2019–2025

Across 725 payments — averaging $746.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$308K
  • Kowa Research Institute, Inc.$101K
  • Novo Nordisk$83K
  • Ironwood Pharmaceuticals, Inc$41K
  • Pfizer$1K
  • Sanofi-aventis U.S. LLC$810
  • plus $7K from 50 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)115$307,757
Kowa Research Institute, Inc.33$100,964
Novo Nordisk127$82,738
Ironwood Pharmaceuticals, Inc10$41,023
Pfizer93$1,119
Sanofi-aventis U.S. LLC14$810
AstraZeneca44$798
Johnson & Johnson36$580
Amgen23$463
GSK19$444
Phathom Pharmaceuticals, Inc.17$423
Lilly USA, LLC15$312
Novartis13$290
Abbott7$236
Avanir Pharmaceuticals, Inc.13$235
Inspire Medical Systems, Inc.12$227
Exact Sciences6$195
Paratek Pharmaceuticals, Inc.9$181
Takeda Pharmaceuticals U.S.A., Inc.13$160
Indivior Inc.5$159
Merck8$144
Gilead2$137
E.r. Squibb & Sons, L.L.C.9$136
Boehringer Ingelheim6$135
Vanda Pharmaceuticals Inc.6$127
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC7$125
Esperion Therapeutics, Inc.4$123
Lundbeck LLC5$98
Eisai Inc.4$81
Regeneron Healthcare Solutions, Inc.5$73
Currax Pharmaceuticals LLC4$72
Teva Pharmaceuticals USA, Inc.4$69
Nestle Healthcare Nutrition Inc.4$68
Tandem Diabetes Care, Inc.1$61
Tolmar, Inc.3$52
Corcept Therapeutics2$52
Sumitomo Pharma America, Inc.2$47
Edwards Lifesciences1$46
Mylan Specialty L.p.2$44
Upsher-smith Laboratories LLC2$43
Verona Pharma, Inc.2$43
Lucid Diagnostics Inc.2$32
Kowa Pharmaceuticals America, Inc.2$31
Astellas Pharma US Inc1$30
Biohaven Pharmaceutical Holding Company Ltd.2$30
Dexcom, Inc.1$22
Daiichi Sankyo Inc.1$21
Biohaven Pharmaceuticals, Inc.1$20
Redhill Biopharma Inc.1$20
Idorsia Pharmaceuticals US Inc1$20
Shire North American Group Inc1$17
Alkermes, Inc.1$16
Medtronic1$15
Xeris Pharmaceuticals, Inc.1$14
Zyla Life Sciences, Inc.1$13
Melinta Therapeutics, LLC1$12

How this compares

$541,201 in reported general payments places this provider in the 95th percentile of 808 internal medicine providers in Rhode Island.

See all internal medicine providers in Rhode Island

Medicare billing

Part B allowed, 2024
$31,172
Medicare patients
94
Services billed
348

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in Lincoln

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →